Recruiting

GLycaemic Outcomes With Whey Protein in ageING

The goal of this placebo-controlled, partial crossover design study is to identify the impact of consuming whey protein before meals on free-living glucose control in older adults living with type 2 diabetes. The primary specific objective is to determine the effect of a thrice daily whey protein pre-meal supplementation at two doses, on glucose excursions over a 7-day free-living period in adults aged 70-90 years of age, living with type 2 diabetes, compared with a non-protein placebo. Participants will consume…

ClinicalTrials.gov IDNCT07285811

PhaseNA

Enrollment32

SponsorUniversity of Birmingham

Age70 Years

SexALL

I'm interested View official listing

Conditions studied

Type 2 Diabetes

About this study

Interventions

Dietary Supplement: Glycaemic control with whey protein — Comparing pre-meal supplementation of whey protein to protein-free placebo.
Dietary Supplement: Glycaemic control with different doses of whey protein — Comparing pre-meal supplementation of moderate whey protein to a low dose of whey protein.

Primary outcomes

Measurement of changes in free-living glycaemic control (7 days, two occasions)
Changes in postprandial glucose concentrations in blood (4 hours, two occasions)
Concentrations of insulin postprandially in blood (4 hours, two occasions)

Eligibility information

* Male or female * 70-90 years old * Type 2 Diabetes (confirmed with glycated haemoglobin (HbA1c) \>6.5% in clinic or in SportExR) * Stable body mass (body mass index (BMI) ≤40kg/m2) * Generally healthy, assessed via a General Health Questionnaire (GHQ) * Some residual beta-cell activity (confirmed with urine test on induction) * Normal or moderately increased albuminuria (needs to be below 300mg/g) * Normal, mildly or moderately decreased glomerular filtration rate (GFR) (needs to be above 45ml/min/1.732). * Able and willing to attend SportExR a total of 5 times: 1 induction and 2 testing visits and 2 return check-up visits. Exclusion Criteria: * \<70 years old and over 90 years of age * Currently on fast-acting insulin therapy (i.e., Humalog) * Confirmed uncontrolled diabetes (HbA1C \>10% or 85mmol/mol). * Currently on GLP-1 therapy * Habitual smoker or vaper * Veganism * Lactose or dairy intolerance * Coeliac or gluten intolerance * History of gastrointestinal disease * Experienced a hyperglycaemic or hypoglycaemic event requiring treatment in the past 12 months * Recent Ischemic stroke (\<3 months). * Use of anticoagulants (e.g. warfarin, rivaroxaban) * Considered unwilling or unable to comply with the study protocol requirements by the research team

Study locations

School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, West Midlands B15 2TT United Kingdom
Heartlands Hospital, Birmingham, United Kingdom

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.